Insider Selling: USANA Health Sciences, Inc. (NYSE:USNA) CEO Sells $147,350.00 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) CEO Jim Brown sold 5,000 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $29.47, for a total value of $147,350.00. Following the completion of the transaction, the chief executive officer now owns 15,716 shares of the company’s stock, valued at $463,150.52. This trade represents a 24.14 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

USANA Health Sciences Stock Up 4.2 %

Shares of NYSE USNA opened at $30.86 on Thursday. USANA Health Sciences, Inc. has a 52-week low of $27.71 and a 52-week high of $50.32. The firm has a fifty day moving average of $33.20 and a 200-day moving average of $36.34. The stock has a market capitalization of $588.10 million, a PE ratio of 10.90, a P/E/G ratio of 0.93 and a beta of 0.98.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The business had revenue of $213.61 million during the quarter, compared to analysts’ expectations of $208.82 million. Equities research analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Institutional Trading of USANA Health Sciences

Institutional investors have recently modified their holdings of the company. R Squared Ltd purchased a new stake in USANA Health Sciences during the 4th quarter worth $28,000. Safe Harbor Fiduciary LLC purchased a new stake in USANA Health Sciences during the 3rd quarter worth $30,000. KBC Group NV boosted its position in USANA Health Sciences by 96.6% during the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after purchasing an additional 519 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in USANA Health Sciences in the fourth quarter valued at approximately $83,000. Finally, Quantbot Technologies LP acquired a new stake in USANA Health Sciences in the fourth quarter valued at approximately $132,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on USNA. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Sidoti cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. Finally, DA Davidson lowered their price target on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, February 27th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.